Related Experiment Video
Updated: Sep 23, 2025
05:38
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
18.2K
Atypical Parkinsonism: Methamphetamine may play a role
Mehri Salari1, Fatemeh Hojjati Pour1, Ronak Rashedi1
1Functional Neurosurgery Research Center, Shohada-e-Tajrish Neurosurgical Center of Excellence Shahid Beheshti University of Medical Sciences Tehran Iran.
Clinical Case Reports
|May 11, 2022
Summary
Methamphetamine abuse may cause or worsen atypical parkinsonian syndromes (APS). This highlights the importance of preventing drug abuse to mitigate neurological risks.
Area of Science:
- Neuroscience
- Toxicology
- Neurology
Background:
- Atypical parkinsonian syndromes (APS) are a group of neurological disorders.
- Methamphetamine is a potent central nervous system stimulant with known neurotoxic effects.
Observation:
- The study examines the potential role of methamphetamine abuse as a causative or exacerbating factor in APS.
Findings:
- Methamphetamine abuse is identified as a potential agent that can induce or influence the progression of atypical parkinsonian syndromes.
Implications:
- Findings underscore the critical need for public health initiatives focused on preventing methamphetamine abuse.
- Understanding this link may inform clinical approaches to diagnosing and managing APS in individuals with a history of substance abuse.
Related Concept Videos
01:24Parkinson's Disease: Treatment
404
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
404
01:15Parkinson's Disease: Overview
738
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
738
01:29Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
412
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
412
01:23Drugs Acting on Autonomic Ganglia: Stimulants
1.6K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.6K
01:25Adrenergic Agonists: Indirect-Acting Agents
1.9K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.9K